531 related articles for article (PubMed ID: 22052128)
41. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
42. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
43. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
[TBL] [Abstract][Full Text] [Related]
44. Clinical value of [(18)F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer.
Jiang J; Yang Z; Zhang Y; Xu X; Wang M; Hu S; Yao Z; Pan H; Zhang Y; Li D
Clin Imaging; 2014; 38(6):797-801. PubMed ID: 24973077
[TBL] [Abstract][Full Text] [Related]
45. Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis.
Lee SW; Shim SR; Jeong SY; Kim SJ
Clin Nucl Med; 2020 May; 45(5):341-348. PubMed ID: 32049723
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
Ong SC; Schöder H; Patel SG; Tabangay-Lim IM; Doddamane I; Gönen M; Shaha AR; Tuttle RM; Shah JP; Larson SM
J Nucl Med; 2007 Apr; 48(4):501-7. PubMed ID: 17401085
[TBL] [Abstract][Full Text] [Related]
47. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.
Faggiano A; Grimaldi F; Pezzullo L; Chiofalo MG; Caracò C; Mozzillo N; Angeletti G; Santeusanio F; Lombardi G; Colao A; Avenia N; Ferolla P
Endocr Relat Cancer; 2009 Mar; 16(1):225-31. PubMed ID: 19004986
[TBL] [Abstract][Full Text] [Related]
48. [
Rasul S; Hartenbach S; Rebhan K; Göllner A; Karanikas G; Mayerhoefer M; Mazal P; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2159-2169. PubMed ID: 29766245
[TBL] [Abstract][Full Text] [Related]
49. 18F-DOPA and 18F-FDG PET/CT, scintigraphic localization and radioguided surgery of recurrent medullary thyroid cancer: two case reports.
Evangelista L; Farsad M; Piotto A; Pelizzo MR
Curr Radiopharm; 2014; 7(2):133-7. PubMed ID: 25355429
[TBL] [Abstract][Full Text] [Related]
50. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?
Slavikova K; Montravers F; Treglia G; Kunikowska J; Kaliska L; Vereb M; Talbot JN; Balogova S
Curr Radiopharm; 2013 Jun; 6(2):96-105. PubMed ID: 23745775
[TBL] [Abstract][Full Text] [Related]
51. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
[TBL] [Abstract][Full Text] [Related]
52. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
[TBL] [Abstract][Full Text] [Related]
53. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
Metser U; You J; McSweeney S; Freeman M; Hendler A
AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
[TBL] [Abstract][Full Text] [Related]
54. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
55. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
Ozkan E; Soydal C; Araz M; Aras G; Ibis E
Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
[TBL] [Abstract][Full Text] [Related]
56. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
57. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
[TBL] [Abstract][Full Text] [Related]
58. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
[TBL] [Abstract][Full Text] [Related]
59. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
60. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.
Szakáll S; Esik O; Bajzik G; Repa I; Dabasi G; Sinkovics I; Agoston P; Trón L
J Nucl Med; 2002 Jan; 43(1):66-71. PubMed ID: 11801705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]